posted
BioElectronics Launches Direct Response Television Initiative 6 minutes ago - Market Wire
BIEL 0.0751 -1.18%
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it is launching a direct response television (DRTV) initiative to market its ActiPatch(R) Therapy and Allay(TM) brands to the mass market. BioElectronics has retained industry leader, Schulberg MediaWorks as its marketing partner. Work on the DRTV spots has already begun with initial airing expected within 60 days. Initially, the Canadian and selected other English speaking markets will be targeted, but the U.S. market will also be heavily targeted once FDA clearance is received.
"We have selected SMW (Schulberg MediaWorks) as our partner based on its impressive record of both success and integrity. SMW, which is one of the pioneers in infomercial advertising, has an impressive track record with more than $700 million in DRTV sales and more than one billion viewers of its innovative programs," commented Andrew Whelan, CEO of BioElectronics. "In addition to impressive creative and video production capabilities, they also bring to the table extensive operational expertise in media buying, web design, order processing, and fulfillment. Our management team and board of directors are pleased that a DRTV firm of SMW's quality has agreed to be our partner. We are expecting this initiative to be a major revenue generator for the Company."
"We believe ActiPatch Therapy and Allay are strong brands for DRTV marketing," commented Jon Schulberg, President of Schulberg MediaWorks. "The issue of the potential dangers of Tylenol(R) and acetaminophen is already resonating with the public and we believe many consumers are looking for drug-free alternatives. We will be working closely with the BioElectronics team to help communicate the message to the public that the ActiPatch Therapy and Allay products are effective alternatives to taking potentially dangerous medications. We look forward to making this initiative a success for BioElectronics and its shareholders."
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
IP: Logged |
posted
Good morning Smash! Biel looks really good. With FDA approval this thing should blast off. What else have you got brewing (besides coffee) this morning?
posted
Yeah thats intersting huh. If I understood correctly,they need some kind of special FDA approval to mass market that drug. I'm a pretty short-term holder, but it could move like crazy on a day they announce FDA approval.
IP: Logged |
posted
i have not done to much research yet, i am also wondering if they have ever tried to get their product approved but the fda failed it? have you heard of any possible dates of when it might be approved by the fda?
-------------------- dont make yourself loose money in a stock that you had a resonable profit in
IP: Logged |
posted
I haven't researched that either, jdizz. Maybe Trade4Pepper would know since they were already in this. Volume is too huge right now. Taking a dip to .079, but chart is oversold to the max. It SHOULD spark a turn around in a sec.
IP: Logged |
posted
Here is a link to the 54 page independant analysis provided. Projected share price of .30-.50 per shre when FDA gives it's blessings, which according to this analysis, is fully expected by September 22nd.
posted
Thanks again trade4pepper. I copied this from the link you gave. I like the last part about $300 to $500 million market cap. This seems like a buy and hold opportunity. Not gonna make a big gain today it looks like.
BioElectronics Corp., which trades under the ticker symbol BIEL is the maker of disposable, inexpensive, drug-free, anti-inflammatory medical devices and patches. Our six-month target price for these shares is $0.30 to $0.50, assuming FDA actions take place as we expect.
The Company was recently awarded a U.S. patent that protects its intellectual property and revolutionary product design for a portable PEMF device that is worn against the skin.
Consumers now have the choice of an effective drug-free therapy-aid in BioElectronics Corporation’s PEMF patches for managing pain, promoting healing and speeding surgical recovery. The recent FDA panel recommendations regarding the potential dangers of acetaminophen, and their corresponding recommendation to remove Extra Strength Tylenol® from store shelves, has damaged Tylenol’s brand equity and is beginning to focus a meaningful amount of attention on BioElectronics.
We believe the market opportunity for the Company's products is significant, especially as related to the treatment of back pain, menstrual pain and general musculoskeletal complaints.
The review of multiple FDA clearances is highly probable. Data from a recently announced heel and foot pain study shows a high degree of efficacy and was produced by a very prominent surgeon. We expect this to lead to rapid FDA clearance. We also believe the AllayTM product will receive FDA clearance.
In our view, it would not be unreasonable to see the total market capitalization of the Company rise to between $300 million and $500 million, if events take place as outlined above.
IP: Logged |
posted
AN UPDATE!!!5 min ago!!!Been moving up all morning before this came out!!
BioElectronics Significantly Strengthens Balance Sheet, Comments on FDA Applications 5 minutes ago - Market Wire
Related Companies Symbol Last %Chg BIEL 0.0795 2.05%
As of 11:16 AM ET 8/19/09 BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today provided the following update to its investors regarding its strengthening balance sheet and a status of FDA filings.
Balance Sheet - Over the past month, the management team of BioElectronics has taken meaningful steps to strengthen the Corporation's balance sheet. Current assets now far exceed current liabilities, allowing the Company to show a current ratio significantly above one. The current ratio is the predominantly accepted indicator of the Company's ability to meet short-term obligations. Additionally, all convertible debt has now been completely eliminated. Andrew Whelan, CEO of BioElectronics, commented, "We are very excited about the very positive changes in our balance sheet. Our growing cash balance, improved working capital situation and the elimination of all convertible debt provides us with a great deal of increased flexibility relative to our operations. When we combine these events with the recent guarantee we received from the U.S. Government's Export-Import Bank, the result is a much lower cost of capital and increased credibility for BioElectronics while we negotiate partnerships arrangements."
FDA Filings - BioElectronics continues to work with its contacts at the FDA on the Company's recently filed pre-market notification application for the Allay Period Relief product and the management team remains confident clearance will be granted. The management team has also decided on a strategy to file at least three additional separate FDA applications over the short-term. These will include separate applications for indications for heel/foot pain, general surgical recovery, and general musculoskeletal complaints. Mr. Whelan added, "We remain very confident relative to our FDA applications. We believe we are right on track with the Allay product and we are working diligently to finalize the other filings. After reviewing the extremely strong and compelling data from Dr. David Genecov's study at our 'All Hands Meeting' earlier this week, we decided it deserves a separate application, therefore we expect to file at least three more applications instead of only two. All of us at BioElectronics are very excited about these very positive trends in our business and we thank all of our investors for their loyal continuing support."
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
